PIK3CA and breast carcinoma: Similarly, Eichhorn et al. showed that the use of a dual PI3K and mTOR inhibitor, NVP-BEZ235, can reverse anti-EGFR/HER2 resistance in HER2+ breast cancers that express low PTEN or contain PIK3CA activating mutations (93).